Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

Biotechnology • Healthcare • Boston, MA, United States • GLUE (NMS)

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

617 949 2643 321 Harrison Avenue, Boston, MA 02118, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Monte Rosa (GLUE) Stock Pre-Market (+8.7%): Positive Phase 1 Data for MRT-8102 - Trefis
Trefis • Jan 7
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - GlobeNewswire
GlobeNewswire • Jan 6
Early trial results for a new drug targeting heart disease risk go public - Stock Titan
Stock Titan • Jan 6
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 8.2% - Here's Why - MarketBeat
MarketBeat • Jan 5
Is MRT-2359 Prostate Cancer Data Update Altering The Investment Case For Monte Rosa Therapeutics (GLUE)? - simplywall.st
simplywall.st • Dec 16

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Monte Rosa Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Monte Rosa Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Monte Rosa Therapeutics, Inc. have?
Monte Rosa Therapeutics, Inc. has approximately 147 employees.
What industry is Monte Rosa Therapeutics, Inc. in?
Monte Rosa Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Monte Rosa Therapeutics, Inc. a publicly traded company?
Yes, Monte Rosa Therapeutics, Inc. is publicly traded under the ticker symbol GLUE on the NMS. The company has a market capitalization of approximately $1.05 billion.
Where is Monte Rosa Therapeutics, Inc. headquartered?
Monte Rosa Therapeutics, Inc. is headquartered in Boston, MA, United States at 321 Harrison Avenue, Boston, MA 02118, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.